Leukemia Therapeutics Market (2010 – 2020)

2011-12-07
Published : Dec-2011

Leukemia is the type of blood cancer and the ninth most common one in males. It accounts for almost 0.0148% of all the men and 0.009% of all the women worldwide. The leukemia market is segmented into four types; namely acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The market was dominated by chronic myeloid leukemia in 2010. However, in 2020, the market is expected to be equally dominated by acute lymphocytic leukemia and chronic myeloid leukemia.

This report studies the market from 2010 to 2020 covering 29 major regimens and single drugs (off-patent and pipeline) for leukemia treatment. The growing population of leukemia is an impetus for the growth of the market. This market is expected to grow at a CAGR of 3.84% from 2015 to 2020. North America was the major contributor to this market; accounting for 61.95% of the total sales of leukemia drugs in 2010; whereas Gleevec was the major drug accounting for 55.48% of the total sales of leukemia drugs in 2010. Leukemia is still an area with high unmet need for early diagnosis and limited treatment options in this area.

The report studies 19 existing regimens and single drugs for leukemia market. Currently, there are about ten major drugs in pipeline for leukemia; which are expecting a market launch by 2012-2014; Talon Therapeutics Inc submitted new drug application to FDA for Marqibo in July 2011, leading to its market launch by 2012.

Quizartinib will be launched in the market in 2012 by Ambit Biosciences Inc (U.S.) on receiving fast track designation approval from the FDA in 2010. The drug is expected to be priced at $21,129 for patients who take them annually.

Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to September 2011.

Pipeline drugs form a major growth strategy in the global leukemia therapeutics market accounting for 28% share between January 2008 and September 2011, followed by approvals with a 25% share, and agreements and collaborations with 24% share.

Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Roche, Bristol-Myers Squibb, Genmab A/S, Celgene Corporation, and Biogen Idec rule the present market for leukemia drugs; whereas Ambit Bioscience & Pfizer are expected to capture major share of the market by 2020.

Scope of the report

This leukemia therapeutics market research report evaluates the leukemia drugs market with respect to the current and pipeline drugs and regimens. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

  • Chemotherapy regimens
    • Hyper-CVAD
    • CALGB 8811 regimen
    • Linker regimen
    • FC regimen
    • FCR regimen
    • DC regimen
    • VCD regimen
    • AVD regimen
  • Chemotherapy drugs
    • Gleevec
    • Sprycel
    • Tasigna
    • Clolar
    • Nelarabine
    • Oncaspar
    • Fludara
    • Campath/MabCampath
    • Treanda
    • Arzerra
    • Cytarabine
  • Pipeline drugs
    • Bosutinib
    • Omapro
    • Vidaza
    • Dacogen
    • Midostaurin
    • Vosaroxin
    • Quizartinib
    • GA101 / RG7159
    • Graspa
    • Marqibo

The geographies covered under the report are

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
  • Japan

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings and future forecasts in consideration.

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 KEY DATA POINTS TAKEN FROM SECONDARY SOURCES
1.5.3 ASSUMPTIONS MADE FOR THIS REPORT

2 EXECUTIVE SUMMARY   
2.1 OVERVIEW OF THE MARKET

3 MARKET OVERVIEW   
3.1 DEFINING LEUKEMIA
3.1.1 DIAGNOSIS
3.1.1.1 Biopsy and bone marrow aspiration
3.1.1.2 Complete blood count (CBC) and differential
3.1.1.3 Philadelphia chromosome’s presence
3.1.1.4 Spinal tap (lumbar puncture) and cerebrospinal fluid (CSF) analysis
3.1.1.5 Immunophenotyping or phenotyping by flow cytometry
3.1.1.6 Polymerase chain reaction (PCR)
3.1.2 LEUKEMIA PREVALENCE
3.1.3 INCIDENCE & MORTALITY
3.2 TYPES OF LEUKEMIA
3.2.1 BASED ON DEVELOPMENTAL & PROGRESSION RATE
3.2.1.1 Chronic leukemia
3.2.1.2 Acute leukemia
3.2.2 BASED ON BONE MARROW CELLS AFFECTED
3.2.2.1 Lymphocytic (lymphoblastic) leukemia
3.2.2.2 Myelogenous (also called myeloid) leukemia
3.2.3 BASED ON DEVELOPMENT/PROGRESSION RATE & TYPE OF BONE MARROW CELLS AFFECTED
3.2.3.1 Acute Lymphocytic Leukemia (ALL)
3.2.3.2 Chronic Lymphocytic Leukemia (CLL)
3.2.3.2.1 B-cell CLL
3.2.3.2.2 T-cell CLL
3.2.3.2.3 Hairy cell leukemia
3.2.3.2.4 Large granular lymphocytic leukemia
3.2.3.3 Acute Myeloid Leukemia (AML)
3.2.3.4 Chronic Myeloid Leukemia (CML)
3.3 STAGES/PHASES OF LEUKEMIA
3.3.1 ACUTE LYMPHOCYTIC LEUKEMIA
3.3.1.1 Childhood ALL
3.3.1.1.1 Standard (low) risk
3.3.1.1.2 High risk
3.3.1.1.3 Recurrent
3.3.1.2 Adult ALL
3.3.1.2.1 Untreated adult ALL
3.3.1.2.2 Adult ALL in remission
3.3.1.2.3 Recurrent adult ALL
3.3.2 CHRONIC LYMPHOCYTIC LEUKEMIA
3.3.2.1 Stage 0
3.3.2.2 Stage I
3.3.2.3 Stage II
3.3.2.4 Stage III
3.3.2.5 Stage IV
3.3.3 ACUTE MYELOID LEUKEMIA
3.3.3.1 Childhood AML
3.3.3.2 Adult AML
3.3.4 CHRONIC MYELOGENOUS LEUKEMIA
3.3.4.1 Chronic stage
3.3.4.2 Accelerated stage
3.3.4.3 Blastic stage
3.3.4.4 Relapse
3.4 MARKET STRUCTURE
3.4.1.1 Key therapies
3.4.1.1.1 Chemotherapy
3.4.1.1.2 Stem cell/bone marrow transplant
3.4.1.1.3 Radiation therapy

4 LEUKEMIA MARKET DYNAMICS   
4.1 MARKET OVERVIEW
4.2 BURNING ISSUES
4.3 WINNING IMPERATIVES
4.3.1 BMS STRATEGY ON PRODUCT EDUCATION THROUGH ONLINE SERVICES
4.4 MARKET DYNAMICS
4.4.1 MARKET DRIVERS
4.4.1.1 Innovative therapies to drive the market for leukemia
4.4.1.2 Oncology is the largest therapeutic market with high unmet needs
4.4.1.3 Off-label prescribing drives market growth.
4.4.2 MARKET RESTRAINTS
4.4.2.1 Adverse events of treatment
4.4.2.2 Low production capability for efficient drugs
4.4.3 MARKET OPPORTUNITIES
4.4.3.1 Limited players in the market
4.4.3.2 Growing older male population
4.4.3.3 Leukemia’s underserved patient populations offer potential for market growth

5 LEUKEMIA PRODUCT MARKET
  5.1 MARKET OVERVIEW
5.1.1 GLEEVEC
5.1.2 SPRYCEL
5.1.3 TASIGNA
5.1.4 CAMPATH/MABCAMPATH
5.1.5 TREANDA
5.1.6 ARZERRA
5.1.7 FLUDARA
5.1.8 FCR REGIMEN
5.1.9 FC REGIMEN
5.1.10 HYPER-CVAD
5.1.11 CALGB 8811 REGIMEN
5.1.12 LINKER REGIMEN
5.1.13 NUCLEOSIDE METABOLIC INHIBITORS (CLOLAR + ARRANON)
5.1.14 ONCASPAR
5.1.15 DAUNORUBICIN + CYTARABINE (FOR INDUCTION)
5.1.16 CYTARABINE (FOR RELAPSE)
5.1.17 DAUNORUBICIN + CYTARABINE (FOR ELDERLY)
5.1.18 VCD REGIMEN (APL)
5.1.19 AVD REGIMEN (APL)

6 LEUKEMIA DRUG PIPELINE (PHASE III)   
6.1 PIPELINE DRUGS
6.1.1 BOSUTINIB
6.1.2 OMAPRO
6.1.3 GA101/RG7159
6.1.4 VIDAZA
6.1.5 DACOGEN
6.1.6 MIDOSTAURIN
6.1.7 VOSAROXIN
6.1.8 QUIZARTINIB
6.1.9 GRASPA
6.1.10 MARQIBO

7 GEOGRAPHIC ANALYSIS   
7.1 U.S.
7.2 CANADA
7.3 U.K.
7.4 GERMANY
7.5 FRANCE
7.6 ITALY
7.7 SPAIN
7.8 JAPAN

8 COMPETITIVE LANDSCAPE   
8.1 INTRODUCTION

9 COMPANY PROFILES   
9.1 AMBIT BIOSCIENCES CORPORATION
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCTS & SERVICES
9.1.4 STRATEGY
9.1.5 DEVELOPMENTS
9.2 ARIAD PHARMACEUTICALS INC
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCTS & SERVICES
9.2.4 DEVELOPMENTS
9.3 BIOGEN IDEC INC.
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCTS & SERVICES
9.3.4 DEVELOPMENTS
9.4 BRISTOL-MYERS SQUIBB
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCTS & SERVICES
9.4.4 STRATEGY
9.4.5 DEVELOPMENTS
9.5 CELGENE CORPORATION
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCTS & SERVICES
9.5.4 STRATEGY
9.5.5 DEVELOPMENTS
9.6 CEPHALON INC
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCTS & SERVICES
9.6.4 STRATEGY
9.6.5 DEVELOPMENTS
9.7 CLAVIS PHARMA ASA
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCTS & SERVICES
9.7.4 STRATEGY
9.7.5 DEVELOPMENTS
9.8 EISAI CO. LTD.
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCTS & SERVICES
9.8.4 STRATEGY
9.8.5 DEVELOPMENTS
9.9 ERYTECH PHARMA
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCTS & SERVICES
9.9.4 STRATEGY
9.9.5 DEVELOPMENTS
9.10 GENMAB A/S
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCTS & SERVICES
9.10.4 STRATEGY
9.10.5 DEVELOPMENTS
9.11 GENZYME CORPORATION
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCTS & SERVICES
9.11.4 STRATEGY
9.11.5 DEVELOPMENTS
9.12 GLAXOSMITHKLINE PLC
9.12.1 OVERVIEW
9.12.2 FINANCIALS
9.12.3 PRODUCTS & SERVICES
9.12.4 STRATEGY
9.12.5 DEVELOPMENTS
9.13 NOVARTIS INTERNATIONAL AG
9.13.1 OVERVIEW
9.13.2 FINANCIALS
9.13.3 PRODUCTS & SERVICES
9.13.4 STRATEGY
9.13.5 DEVELOPMENTS
9.14 PFIZER INC
9.14.1 OVERVIEW
9.14.2 FINANCIALS
9.14.3 PRODUCTS & SERVICES
9.14.4 STRATEGY
9.14.5 DEVELOPMENTS
9.15 ROCHE HOLDING AG
9.15.1 OVERVIEW
9.15.2 FINANCIALS
9.15.3 PRODUCTS & SERVICES
9.15.4 STRATEGY
9.15.5 DEVELOPMENTS
9.16 SUNESIS PHARMACEUTICALS INC
9.16.1 OVERVIEW
9.16.2 FINANCIALS
9.16.3 PRODUCTS & SERVICES
9.16.4 STRATEGY
9.16.5 DEVELOPMENTS
9.17 TALON THERAPEUTICS INC
9.17.1 OVERVIEW
9.17.2 FINANCIALS
9.17.3 PRODUCTS & SERVICES
9.17.4 STRATEGY
9.17.5 DEVELOPMENTS

LIST OF TABLES    

TABLE 1 YEARLY COST OF DRUGS IN NORTH AMERICA & JAPAN, 2011 ($)
TABLE 2 YEARLY COST OF DRUGS IN EUROPEAN COUNTRIES, 2011 ($)
TABLE 3 DOSAGE PATTERN OF DRUGS
TABLE 4 LEUKEMIA DRUGS MARKET REVENUE, BY REGIMENS/DRUGS, 2008 – 2020 ($MILLION)
TABLE 5 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS – PATENT STATUS
TABLE 6 CHRONIC LYMPHOCYTIC LEUKEMIA DRUGS – PATENT STATUS
TABLE 7 CHRONIC MYELOID LEUKEMIA DRUGS – PATENT STATUS
TABLE 8 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)
TABLE 9 CHRONIC LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)
TABLE 10 ACUTE MYELOID LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)
TABLE 11 CHRONIC MYELOID LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)
TABLE 12 AGED MALE POPULATION GROWTH, 2010 – 2025 (THOUSAND)
TABLE 13 LEUKEMIA DRUG/REGIMENS MARKET REVENUE, 2008 – 2020 ($MILLION)
TABLE 14 LEUKEMIA DRUGS (GLEEVEC) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 15 LEUKEMIA DRUGS (SPRYCEL) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 16 LEUKEMIA DRUGS (TASIGNA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 17 LEUKEMIA DRUGS (CAMPATH) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 18 LEUKEMIA DRUGS (TREANDA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 19 LEUKEMIA DRUGS (ARZERRA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 20 LEUKEMIA DRUGS (FLUDARA) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 21 LEUKEMIA REGIMEN (FCR) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 22 LEUKEMIA REGIMEN (FC) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 23 LEUKEMIA REGIMEN (HYPER-CVAD) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 24 LEUKEMIA REGIMEN (CALGB 8811) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 25 LEUKEMIA DRUGS (LINKER REGIMEN) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 26 LEUKEMIA DRUG CLASS (NUCLEOSIDE METABOLIC INHIBITORS) MARKET REVENUE, BY COUNTRY, 2008 – 2020  ($MILLION)
TABLE 27 LEUKEMIA DRUGS (ONCASPAR) MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 28 LEUKEMIA DC REGIMEN MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 29 LEUKEMIA CYTARABINE MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 30 LEUKEMIA DC REGIMEN FOR ELEDERLY MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 31 LEUKEMIA VCD REGIMEN MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 32 LEUKEMIA AVD REGIMEN MARKET REVENUE, BY COUNTRY, 2008 – 2020 ($MILLION)
TABLE 33 LEUKEMIA DRUGS – PIPELINE (BOSUTINIB) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 34 LEUKEMIA DRUGS – PIPELINE (OMAPRO) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 35 LEUKEMIA DRUGS – PIPELINE (GA 101/RG 7159) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 36 LEUKEMIA DRUGS – PIPELINE (VIDAZA) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 37 LEUKEMIA DRUGS – PIPELINE (DACOGEN) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 38 LEUKEMIA DRUGS – PIPELINE (MIDOSTAURIN) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 39 LEUKEMIA DRUGS – PIPELINE (VOSAROXIN) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 40 LEUKEMIA DRUGS – PIPELINE (QUIZARTINIB) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 41 LEUKEMIA DRUGS – PIPELINE (GRASPA) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 42 LEUKEMIA DRUGS – PIPELINE (MARQIBO) MARKET REVENUE, BY COUNTRY, 2015 – 2020 ($MILLION)
TABLE 43 SEER STATISTICS FOR LEUKEMIA (ESTIMATED) IN U.S., 2011
TABLE 44 U.S: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 45 U.S: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2008 – 2020 ($MILLION)
TABLE 46 CANADA: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 47 CANADA: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)
TABLE 48 U.K: INCIDENCE BY GENDER & TYPE OF LEUKEMIA, 2010
TABLE 49 U.K: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 50 U.K: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)
TABLE 51 GERMANY: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 52 GERMANY: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)
TABLE 53 FRANCE: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 54 FRANCE: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)
TABLE 55 ITALY: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 56 ITALY: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2015 – 2020 ($MILLION)
TABLE 57 SPAIN: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 58 SPAIN: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2008 – 2020 ($MILLION)
TABLE 59 JAPAN: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 – 2020 ($MILLION)
TABLE 60 JAPAN: LEUKEMIA DRUGS – PIPELINE MARKET REVENUE, BY DRUGS, 2008 – 2020 ($MILLION)
TABLE 61 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES
TABLE 62 NEW PRODUCTS LAUNCH, 2008 – 2011
TABLE 63 EXPANSIONS/NEW FACILITY/INVESTMENTS, 2011
TABLE 64 FDA APPROVALS, 2008 – 2011
TABLE 65 PHASE III CLINICAL TRIALS, 2008 – 2011
TABLE 66 NDA, BLA & MARKETING APPLICATIONS, 2008 – 2011
TABLE 67 AMBIT BIOSCIENCES: PRODUCT PIPELINE
TABLE 68 ARIAD PHARMACEUTICALS: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 69 ARIAD PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 70 BIOGEN IDEC INC: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 71 BIOGEN IDEC INC: EXISTING PRODUCT & PIPELINE PRODUCT PORTFOLIO
TABLE 72 BRISTOL-MYERS SQUIBB: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 73 BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 74 CELGENE CORPORATION: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 75 CELGENE CORPORATION: PRODUCT PIPELINE
TABLE 76 CEPHALON INC: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 77 CEPHALON INC: PRODUCT PORTFOLIO
TABLE 78 CLAVIS PHARMA ASA: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 79 CLAVIS PHARMA ASA: PRODUCT PORTFOLIO
TABLE 80 EISAI CO. LTD: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 81 ISAI CO. LTD: PRODUCT PIPELINE
TABLE 82 ERYTECH PHARMA: PRODUCT PIPELINE
TABLE 83 GENMAB A/S: TOTAL REVENUE & R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 84 GENMAB A/S: EXISTING PRODUCT &PIPELINE PRODUCT PORTFOLIO
TABLE 85 GENZYME CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 86 GENZYME CORPORATION: PRODUCT PORTFOLIO
TABLE 87 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 88 GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 89 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 90 NOVARTIS INTERNATIONAL AG: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 91 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 92 PFIZER INC: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 93 ROCHE HOLDING: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 94 ROCHE HOLDINGS: MARKET REVENUE, BY BUSINESS SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 95 ROCHE HOLDINGS: EXISTING & PIPELINE PRODUCT PORTFOLIO
TABLE 96 SUNESIS PHARMACEUTICALS INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 97 SUNESIS PHARMACEUTICALS INC: PRODUCT PIPELINE
TABLE 98 TALON THERAPEUTICS INC: TOTAL R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 99 TALON THERAPEUTICS INC: PIPELINE PRODUCT PORTFOLIO

LIST OF FIGURES    

FIGURE 1 TOTAL LEUKEMIA MARKET, 2008 – 2020 ($MILLION)
FIGURE 2 LEUKEMIA MARKET REVENUE, BY TYPES, 2008 – 2020 ($MILLION)
FIGURE 3 LEUKEMIA POPULATION, BY COUNTRY, 2008 – 2020
FIGURE 4 LEUKEMIA DEVELOPMENT & PROGRESSION RATE, BY AGE
FIGURE 5 TYPES OF LEUKEMIA
FIGURE 6 ACUTE LYMPHOCYTIC LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS
FIGURE 7 ACUTE LYMPHOCYTIC LEUKEMIA: EXISTING DRUGS MARKET SHARE, 2010 VS 2020
FIGURE 8 ACUTE LYMPHOCYTIC LEUKEMIA: PIPELINE DRUGS MARKET SHARE, 2015 VS 2020
FIGURE 9 CHRONIC LYMPHOCYTIC LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS
FIGURE 10 CHRONIC LYMPHOCYTIC LEUKEMIA: EXISTING & PIPELINE REGIMENS/DRUGS MARKET SHARE, 2010 VS 2020    FIGURE 11 ACUTE MYELOID LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS
FIGURE 12 ACUTE MYELOID LEUKEMIA: EXISTING REGIMENS/DRUGS MARKET SHARE, 2010 VS 2020
FIGURE 13 ACUTE MYELOID LEUKEMIA: PIPELINE DRUGS MARKET SHARE, 2015 VS 2020
FIGURE 14 CHRONIC MYELOID LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS
FIGURE 15 CHRONIC MYELOID LEUKEMIA: EXISTING REGIMENS/DRUGS MARKET SHARE, 2010 VS 2020
FIGURE 16 CHRONIC MYELOID LEUKEMIA: PIPELINE DRUGS MARKET SHARE,  2015 VS 2020
FIGURE 17 LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 18 LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 19 U.S: INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 20 U.S: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020 ($MILLION)
FIGURE 21 U.S: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 22 CANADA: INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 23 CANADA: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 & 2020
FIGURE 24 CANADA: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 25 U.K: INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 26 U.K: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 27 U.K: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 28 GERMANY: INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 29 GERMANY: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 & 2020
FIGURE 30 GERMANY: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 31 FRANCE: INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 32 FRANCE: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 33 FRANCE: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 34 ITALY: INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 35 ITALY: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 36 ITALY: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 37 SPAIN INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 38 SPAIN EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 39 SPAIN: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 – 2020
FIGURE 40 JAPAN: INCIDENCE & MORTALITY CASES, 2008 – 2020
FIGURE 41 JAPAN: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
FIGURE 42 JAPAN: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
FIGURE 43 KEY GROWTH STRATEGIES (JANUARY 2008 – SEPTEMBER 2011)

Filed in: Pharmaceutical, Therapeutics
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
 $

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
 $4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
 $4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
 $4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy